Maxime Cordonnier
Director of Finance/CFO at AFYREN
Profile
Maxime Cordonnier is currently the Chief Financial Officer at Afyren SAS since 2019.
Prior to this, he held Director positions at Carbiolice SAS, Evertree SAS, and Yposkesi from 2016 to 2018.
He was also a Manager-Business Research at Lundbeck SAS from 2009 to 2010.
Mr. Cordonnier received his graduate degree from Imperial College London in 2005 and his undergraduate degree from École Centrale Paris in the same year.
Maxime Cordonnier active positions
| Companies | Position | Start |
|---|---|---|
| AFYREN | Director of Finance/CFO | 2018-12-31 |
Former positions of Maxime Cordonnier
| Companies | Position | End |
|---|---|---|
Evertree SAS
 Evertree SAS Chemicals: SpecialtyProcess Industries Evertree SAS produces plant-based chemicals. Its product SynerXiD is a family of proprietary, dry powder chemicals for industrial manufacturing. The company was founded by Anthony Parker and Joe Marcinko on February 16, 2016 and is headquartered in Compiegne, France. | Director/Board Member | 2018-11-30 |
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Director/Board Member | 2018-05-31 |
Carbiolice SAS
 Carbiolice SAS Miscellaneous ManufacturingProducer Manufacturing Carbiolice SAS engages in the provision of biological technologies for plastics and synthetic fibers. The company was founded on June 14, 2016 and is headquartered in Riom, France. | Director/Board Member | 2018-05-31 |
Lundbeck SAS
 Lundbeck SAS Pharmaceuticals: MajorHealth Technology Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France. | Corporate Officer/Principal | 2010-11-30 |
Training of Maxime Cordonnier
| Imperial College London | Graduate Degree |
| École Centrale Paris | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AFYREN | Health Technology |
| Private companies | 4 |
|---|---|
Lundbeck SAS
Lundbeck SAS Pharmaceuticals: MajorHealth Technology Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France. | Health Technology |
Carbiolice SAS
Carbiolice SAS Miscellaneous ManufacturingProducer Manufacturing Carbiolice SAS engages in the provision of biological technologies for plastics and synthetic fibers. The company was founded on June 14, 2016 and is headquartered in Riom, France. | Producer Manufacturing |
Evertree SAS
Evertree SAS Chemicals: SpecialtyProcess Industries Evertree SAS produces plant-based chemicals. Its product SynerXiD is a family of proprietary, dry powder chemicals for industrial manufacturing. The company was founded by Anthony Parker and Joe Marcinko on February 16, 2016 and is headquartered in Compiegne, France. | Process Industries |
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
- Stock Market
- Insiders
- Maxime Cordonnier
